1. Scrip
  2. >>Business
  3. >>Earnings

BioMarin’s Voxzogo Expected To Benefit From ‘Sticky’ Nature Of Achondroplasia Market

 
• By Alaric DeArment

Sales for the drug grew significantly, with an exec telling the fourth-quarter earnings call that patients with achondroplasia tend to stick with the drugs they are using.

Brisbane, CA, USA - Mar 1, 2020: The BioMarin logo seen at American biotechnology company BioMarin Pharmaceutical Inc.'s office in Brisbane, California.
• Source: Shutterstock

BioMarin Pharmaceuticals foresees its achondroplasia drug Voxzogo (vosoritide) having a strong competitive position in the years to come given the drug’s established position and the “stickiness” of the market, meaning the tendency for patients to stick to one therapy rather than switching. Voxzogo’s solid performance contributed heavily to the firm’s fourth quarter growth.

The drug maker announced its earnings on 19 February, reporting fourth quarter sales of $747m, a 16% increase over the fourth quarter of 2023, while full-year sales were $2.9bn, an...

Key Takeaways
  • BioMarin reported sales of $747m for the fourth quarter, which beat investor and analyst forecasts, along with $2.9bn for the full year, with Voxzogo playing...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

HHS Intensifies Pressure On Pharma With MFN Pricing Benchmark

 
• By Jessica Merrill

The Trump administration released more details on “most favored nation” price targets drug companies are expected to apply to US drug prices.

Stock Watch: Bayer, Bavarian Nordic Bring European Cheer To Pharma

 
• By Andy Smith

Investors welcomed Bavarian Nordic’s and Bayer’s earnings announcements. However, both stock prices declined over the day of their reports as the impact of recent pressures weighed.

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

 
• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.

More from Scrip

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.

End Is Nigh For 4SC After EMA’s No For Kinselby

 
• By Kevin Grogan

The German biotech has discontinued the oral HDAC inhibitor for cutaneous T-cell lymphoma.

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 
• By Sushmita Panda

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.